Literature DB >> 23070914

Molecular cloning, expression and purification of recombinant soluble mouse endostatin as an anti-angiogenic protein in Escherichia coli.

Kheirollah Yari1, Saboor Afzali, Hadi Mozafari, Kamran Mansouri, Ali Mostafaie.   

Abstract

Inhibition of angiogenesis has become a particular interest for treatment of solid tumors. Endostatin, a C-terminal fragment of collagen XVIII, has been reported to exhibit potent inhibitory effect on endothelial cells proliferation, migration and tube formation. In this research, the cDNA library of endostatin was synthesized from mouse liver and inserted into the SacI and SalI enzyme-cutting sites of pUC18 cloning vector. The recombinant vector was transferred into Escherichia coli DH5a and the recombinant clone was selected on LB agar plate plus ampicillin. PCR analysis and DNA sequencing proved the presence of intact endostatin gene in pUC18. The endostatin gene subcloned into pET32a expression vector and the competent bacterial cells of E. coli BL21 were transformed by the vector harboring endostatin gene. In the optimum conditions, expression plasmid was induced with IPTG and recombinant soluble endostatin as a fusion with thioredoxin was purified with Ni-NTA (Ni(2+)-nitrilotriacetate) resin. The results showed that soluble recombinant endostatin as a fusion protein with thioredoxin is a homogenous polypeptide that inhibits angiogenesis (capillary tube formation) in human umbilical vein endothelial cells by 200 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070914     DOI: 10.1007/s11033-012-2144-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  20 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

2.  Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells.

Authors:  Chandra Shekhar Boosani; Akulapalli Sudhakar
Journal:  Protein Expr Purif       Date:  2006-04-03       Impact factor: 1.650

Review 3.  Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.

Authors:  Judah Folkman
Journal:  Exp Cell Res       Date:  2005-12-22       Impact factor: 3.905

4.  Simultaneous substitution of Gly96 to Ala and Ala183 to Thr in 5-enolpyruvylshikimate-3-phosphate synthase gene of E. coli (k12) and transformation of rapeseed (Brassica napus L.) in order to make tolerance to glyphosate.

Authors:  Danial Kahrizi; Ali Hatef Salmanian; Afsoon Afshari; Ahmad Moieni; Amir Mousavi
Journal:  Plant Cell Rep       Date:  2006-07-28       Impact factor: 4.570

5.  High level expression of recombinant BoNT/A-Hc by high cell density cultivation of Escherichia coli.

Authors:  Kheirollah Yari; Seyed Safa-Ali Fatemi; Mahmood Tavallaei
Journal:  Bioprocess Biosyst Eng       Date:  2011-08-11       Impact factor: 3.210

6.  Endostatin induces endothelial cell apoptosis.

Authors:  M Dhanabal; R Ramchandran; M J Waterman; H Lu; B Knebelmann; M Segal; V P Sukhatme
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

Review 7.  Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

Authors:  Tanya A Rege; Constance Y Fears; Candece L Gladson
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

8.  Expression of soluble, biologically active recombinant human endostatin in Escherichia coli.

Authors:  Han-Mei Xu; Guo-Yuan Zhang; Xiao-Dan Ji; Lin Cao; Luan Shu; Zi-Chun Hua
Journal:  Protein Expr Purif       Date:  2005-06       Impact factor: 1.650

9.  Anti-angiogenic cues from vascular basement membrane collagen.

Authors:  P C Colorado; A Torre; G Kamphaus; Y Maeshima; H Hopfer; K Takahashi; R Volk; E D Zamborsky; S Herman; P K Sarkar; M B Ericksen; M Dhanabal; M Simons; M Post; D W Kufe; R R Weichselbaum; V P Sukhatme; R Kalluri
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

10.  Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway.

Authors:  Martin H Deininger; Wolfgang A Wybranietz; Florian T C Graepler; Ulrich M Lauer; Richard Meyermann; Hermann J Schluesener
Journal:  FASEB J       Date:  2003-07       Impact factor: 5.191

View more
  6 in total

1.  Cloning and Expression of Recombinant Human Endostatin in Periplasm of Escherichia coli Expression System.

Authors:  Abbas Mohajeri; Yones Pilehvar-Soltanahmadi; Mohammad Pourhassan-Moghaddam; Jalal Abdolalizadeh; Pouran Karimi; Nosratollah Zarghami
Journal:  Adv Pharm Bull       Date:  2016-06-30

2.  Association analysis of FAS-670A/G and FASL-844C/T polymorphisms with risk of generalized aggressive periodontitis disease.

Authors:  Rezvan Asgari; Kheirollah Yari; Kamran Mansouri; Mitra Bakhtiari
Journal:  Biomed Rep       Date:  2018-02-08

3.  Expression and Secretion of Endostar Protein by Escherichia Coli: Optimization of Culture Conditions Using the Response Surface Methodology.

Authors:  Abbas Mohajeri; Jalal Abdolalizadeh; Younes Pilehvar-Soltanahmadi; Farhad Kiafar; Nosratollah Zarghami
Journal:  Mol Biotechnol       Date:  2016-10       Impact factor: 2.695

4.  Genetic diversity analysis of Chrysopidae family (Insecta, Neuroptera) via molecular markers.

Authors:  Kheirollah Yari; Alinaghi Mirmoayedi; Marzieh Marami; Elham Kazemi; Danial Kahrizi
Journal:  Mol Biol Rep       Date:  2014-06-29       Impact factor: 2.316

5.  Effect of Culture Condition Variables on Human Endostatin Gene Expression in Escherichia coli Using Response Surface Methodology.

Authors:  Abbas Mohajeri; Yones Pilehvar-Soltanahmadi; Jalal Abdolalizadeh; Pouran Karimi; Nosratollah Zarghami
Journal:  Jundishapur J Microbiol       Date:  2016-05-08       Impact factor: 0.747

Review 6.  The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.

Authors:  Abbas Mohajeri; Sarvin Sanaei; Farhad Kiafar; Amir Fattahi; Majid Khalili; Nosratollah Zarghami
Journal:  Adv Pharm Bull       Date:  2017-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.